A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease
The objective of this position statement from the Saudi Gastroenterology Association is to guide gastroenterologists on the use of tumor necrosis factor-alfa (TNF-α) antagonists for the treatment of the idiopathic inflammatory bowel diseases, Crohn’s disease, and ulcerative colitis. In this article,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2015-01-01
|
| Series: | The Saudi Journal of Gastroenterology |
| Subjects: | |
| Online Access: | http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2015;volume=21;issue=4;spage=185;epage=197;aulast=Mosli |
| id |
doaj-c7a503d42bc743edb5affe7486312320 |
|---|---|
| record_format |
Article |
| spelling |
doaj-c7a503d42bc743edb5affe74863123202020-11-25T01:57:12ZengWolters Kluwer Medknow PublicationsThe Saudi Journal of Gastroenterology1319-37671998-40492015-01-0121418519710.4103/1319-3767.161635A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel diseaseMahmoud H MosliOthman Al-HarbiBrian G FeaganMajid A AlmadiThe objective of this position statement from the Saudi Gastroenterology Association is to guide gastroenterologists on the use of tumor necrosis factor-alfa (TNF-α) antagonists for the treatment of the idiopathic inflammatory bowel diseases, Crohn’s disease, and ulcerative colitis. In this article, we summarize the relevant literature regarding the safety and efficacy of TNF-α antagonists, highlight relevant safety concerns specific to the environment in Saudi Arabia, and provide specific recommendations for the use of these agents.http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2015;volume=21;issue=4;spage=185;epage=197;aulast=MosliCrohn’s diseaseinflammatory bowel diseaseposition statementSaudi Gastroenterology AssociationTNF antagonistsulcerative colitis |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Mahmoud H Mosli Othman Al-Harbi Brian G Feagan Majid A Almadi |
| spellingShingle |
Mahmoud H Mosli Othman Al-Harbi Brian G Feagan Majid A Almadi A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease The Saudi Journal of Gastroenterology Crohn’s disease inflammatory bowel disease position statement Saudi Gastroenterology Association TNF antagonists ulcerative colitis |
| author_facet |
Mahmoud H Mosli Othman Al-Harbi Brian G Feagan Majid A Almadi |
| author_sort |
Mahmoud H Mosli |
| title |
A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease |
| title_short |
A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease |
| title_full |
A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease |
| title_fullStr |
A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease |
| title_full_unstemmed |
A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease |
| title_sort |
saudi gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease |
| publisher |
Wolters Kluwer Medknow Publications |
| series |
The Saudi Journal of Gastroenterology |
| issn |
1319-3767 1998-4049 |
| publishDate |
2015-01-01 |
| description |
The objective of this position statement from the Saudi Gastroenterology Association is to guide gastroenterologists on the use of tumor necrosis factor-alfa (TNF-α) antagonists for the treatment of the idiopathic inflammatory bowel diseases, Crohn’s disease, and ulcerative colitis. In this article, we summarize the relevant literature regarding the safety and efficacy of TNF-α antagonists, highlight relevant safety concerns specific to the environment in Saudi Arabia, and provide specific recommendations for the use of these agents. |
| topic |
Crohn’s disease inflammatory bowel disease position statement Saudi Gastroenterology Association TNF antagonists ulcerative colitis |
| url |
http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2015;volume=21;issue=4;spage=185;epage=197;aulast=Mosli |
| work_keys_str_mv |
AT mahmoudhmosli asaudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease AT othmanalharbi asaudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease AT briangfeagan asaudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease AT majidaalmadi asaudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease AT mahmoudhmosli saudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease AT othmanalharbi saudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease AT briangfeagan saudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease AT majidaalmadi saudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease |
| _version_ |
1724975644011397120 |